KD Biopharma

KD Biopharma is the pharmaceutical manufacturing division of the KD Pharma Group, a global leader in Omega-3 fatty acid technologies. Established following the acquisition of Simeon Pharma's assets in 2015, the company operates as a specialized contract development and manufacturing organization (CDMO) focused on high-purity lipid APIs. KD Biopharma utilizes advanced separation technologies, such as supercritical fluid chromatography and molecular distillation, to produce customized concentrations of EPA and DHA. The company provides end-to-end services ranging from raw material sourcing and purification to softgel encapsulation and packaging. Their products are primarily utilized in the development of treatments for cardiovascular health, metabolic disorders, and neurological conditions.